Highlights
- Honasa Consumer acquired a 58% majority stake in Fluence Pharma.
- Acquisition marks the company's entry into India's nutraceuticals segment.
- Honasa Health will lead the new business through a dedicated subsidiary.
Honasa Consumer Limited (NSE:HONASA) has announced the acquisition of a 58% majority stake in Fluence Pharma, marking its entry into the nutraceuticals category. The company disclosed the development through a press release submitted to the National Stock Exchange and BSE on June 23, 2026.
The acquisition is aimed at expanding Honasa Consumer's presence into science-backed "inside-out" beauty solutions by combining topical beauty products with nutritional support.
Source: Analysis by Kalkine
Dedicated Subsidiary to Drive New Business
To execute its nutraceuticals strategy, Honasa Consumer has established a wholly dedicated subsidiary, Honasa Health Private Limited.
According to the company, the subsidiary will build a business-to-consumer nutraceuticals portfolio by combining Fluence Pharma's patented clinical science and practitioner network with Honasa's digital-first distribution capabilities, consumer insights and brand-building expertise.
The company said India's nutraceuticals market is currently valued at over INR 16,000 crore and is witnessing increasing consumer demand for holistic wellness and beauty-from-within solutions.
Fluence Pharma Brings Patented Technology
Founded by Amit Bhusari and Dr. Rajendra Singh Rajput, Fluence Pharma focuses on science-backed nutraceutical products using its patented Cyclical Nutrition Therapy (CNT).
The company develops condition-specific and gender-specific over-the-counter nutritional supplements for hair and skin concerns. Its technology is supported by patents in India and the United States.
Fluence Pharma said its products have been tested through more than a decade of clinical use and are prescribed by a network of over 3,000 practicing dermatologists across India.
For FY26, Fluence Pharma reported revenue of approximately INR 40 crore and an EBITDA margin exceeding 20%.
CEO Commentary on the Acquisition
Commenting on the acquisition, Varun Alagh, Co-founder and CEO, Honasa Consumer Limited, said:
"The beauty and personal care landscape is entering a new era where consumers are increasingly seeking holistic, inside-out solutions that address beauty concerns at their root. While the last decade was shaped by topical actives, we believe the next decade will be defined by the powerful convergence of science-backed skin and hair care, and nutraceuticals.
Fluence has built a strong scientific foundation through its patented Cyclical Nutrition Therapy, setting a benchmark for clinically validated efficacy. We are excited to build on this foundation and scale it through Honasa Health, creating a consumer-first nutraceuticals franchise that complements our science-led beauty portfolio. This marks an important step in our vision of building a future-ready House of Brands and a more resilient, diversified growth engine."
Leadership for Honasa Health
Honasa Health will be led by Dheeraj Nagpal as Chief Executive Officer.
According to the company, Nagpal has over 15 years of experience in consumer businesses and previously co-founded nutraceutical brand Zingavita. He has also held leadership roles at Zomato and American Express.
Honasa stated that the subsidiary will leverage Fluence Pharma's patented science and dermatologist network while using its own digital ecosystem to build a consumer nutraceutical business.
Fluence Pharma Management Statement
Amit Bhusari, CEO and Co-founder, Fluence Pharma, said:
"For the past ten years, we have focused rigorously on grounding our portfolio in science and earning the trust of the medical fraternity. To unlock the true potential of our proprietary science, however, we needed a partner who could take these clinical solutions to a wider consumer base. Honasa Consumer brings the perfect opportunity and infrastructure for us. Their unparalleled digital-first capabilities, data-driven consumer insights, and proven track record of scaling young brands will allow us to strengthen our distribution and solve consumer problems across India."
Key Risks
- Integration of acquired business may require execution across operations.
- Nutraceutical industry remains subject to evolving regulatory requirements.
- Consumer adoption may influence future growth in the new category.
- Competitive landscape could affect expansion in nutraceutical products.
Summary
Honasa Consumer has acquired a 58% stake in Fluence Pharma, entering India's nutraceuticals market through its newly formed subsidiary, Honasa Health. The acquisition combines Fluence's patented Cyclical Nutrition Therapy platform and dermatologist network with Honasa's digital-first distribution and consumer brand capabilities to build a business-to-consumer nutrition portfolio.
FAQs
Q: What stake has Honasa Consumer acquired in Fluence Pharma?
A: Honasa Consumer has acquired a 58% majority stake in Fluence Pharma to enter the nutraceuticals business.
Q: What is the purpose of Honasa Health Private Limited?
A: Honasa Health will serve as the company's dedicated subsidiary for building its consumer nutraceuticals business.
Q: What were Fluence Pharma's reported FY26 financials?
A: Fluence Pharma reported approximately INR 40 crore revenue and an EBITDA margin exceeding 20% during FY26.